Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
1 other identifier
observational
400
1 country
1
Brief Summary
This study aims to explore whether adding an additional MRI sequence to routine liver scans can better characterize the immune microenvironment of liver cancer. We plan to prospectively enroll patients diagnosed with or suspected of having liver cancer who undergo routine MRI examinations. In addition to the standard MRI protocol, participants will receive one extra MRI sequence. We will analyze the imaging features from this additional sequence and combine them with clinical data to construct a multi-omics model. The goal is to identify imaging biomarkers that can reflect the dynamic changes of the tumor microenvironment, which may help improve the diagnosis and clinical management of liver cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2024
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2024
CompletedFirst Submitted
Initial submission to the registry
August 10, 2026
CompletedFirst Posted
Study publicly available on registry
September 24, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2028
September 24, 2026
September 1, 2026
2.7 years
August 10, 2026
September 22, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
The primary outcomes of this study were PFS
PFS was calculated from the time of receiving treatment to disease progression or death, whichever occurred first, and progression was determined based on contrast-enhanced CT or MRI scans following mRECIST criteria
Up to 24 months after baseline MRI
Interventions
Time-dependent Diffusion MRI: This is a specialized MRI technique that measures water molecule diffusion at different time intervals to probe tissue microstructural features. In tumor tissues with dense cellularity and complex architecture, water diffusion is restricted. This technique allows for the detection of changes in cell size, shape, and interstitial spaces in liver cancer, providing insights into tumor heterogeneity and microenvironment. CEST (Chemical Exchange Saturation Transfer): This is a molecular imaging technique based on chemical exchange. It selectively saturates exchangeable protons on specific molecules (such as proteins, peptides, or metabolites) and detects the transfer of this saturation effect to water protons, enabling indirect measurement of specific molecule concentrations in vivo. In liver cancer research, CEST can detect protein content, pH changes, and metabolic abnormalities in tumor tissues, providing functional information to assess tumor biological be
Eligibility Criteria
Consecutive patients with suspected primary HCC detected on ultrasound or CT at our institution or referring hospitals were prospectively enrolled. All participants underwent EOB-MRI, including Td-dMRI and conventional sequences.
You may qualify if:
- age 18 years or older, (b) pathologically confirmed HCC with available pathology slides, and (c) EOB-MRI including Td-dMRI within 1 month before surgery.
You may not qualify if:
- (a) lesions smaller than 1 cm, (b) poor imaging quality, and (c) received other treatments before surgery.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tongji Hospitallead
Study Sites (1)
Tongji Hospital
Wuhan, Hubei, 430000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 24 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief Physician, Professor
Study Record Dates
First Submitted
August 10, 2026
First Posted
September 24, 2026
Study Start
October 1, 2024
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2028
Last Updated
September 24, 2026
Record last verified: 2026-09